Search Results
Your search for ,ARE matches 21644 pages
Showing 13001 - 13050IMPAKT 2017: Luminal Androgen Receptor Subtype of Triple-Negative Breast Cancer Demonstrates Sensitivity to CDK4/6 Inhibition
Researchers have identified a subtype of triple-negative breast cancer that may be responsive to inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), according to findings presented by Asghar et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract 44P). This study also...
IMPAKT 2017: High Baseline Tumor-Infiltrating Lymphocyte Levels Signal Superior Responses in HER2-Positive Breast Cancer
Baseline levels of tumor-infiltrating lymphocytes (TILs) in pretreatment biopsies from patients with HER2-positive breast cancer are significantly associated with pathologic complete response rates following neoadjuvant chemotherapy plus anti-HER2 agents (trastuzumab [Herceptin], lapatinib...
WHO to Begin Pilot Prequalification of Biosimilars for Cancer Treatment
This year, the World Health Organization (WHO) will launch a pilot project for prequalifying biosimilar medicines, a step toward making some of the most expensive treatments for cancer more widely available in low- and middle-income countries. The decision comes after a 2-day meeting in Geneva...
ASCO Provisional Clinical Opinion: Second-Line Hormonal Therapy for Chemotherapy-Naive Castration-Resistant Prostate Cancer
As reported by Katherine S. Virgo, PhD, MBA, of Emory University, and colleagues in the Journal of Clinical Oncology, ASCO has issued a provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer. The provisional clinical opinion applies...
Germline Genetic Testing and Treatment Decisions in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology by Kurian et al, surveys in a population-based sample of patients recently diagnosed with breast cancer indicate that many undergo genetic risk testing without seeing a genetics counselor and that many with BRCA1/2 variants of uncertain significance...
New Spanish-Language Videos and Brochures From ASTRO Provide an Overview of Radiation Therapy
Spanish-speaking patients with cancer have new tools to help them understand treatment options for their disease. The American Society for Radiation Oncology (ASTRO) has released a series of Spanish-language patient videos on radiation therapy for cancer, including breast, prostate, lung, brain,...
PD-L1 Expression and Radiation Resistance in Head and Neck Squamous Cell Carcinoma
According to a study by Skinner et al, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck squamous cell carcinoma is sensitive to radiation, HPV-negative tumors are...
Cancer Mortality Trends in the United States Vary Widely by County From 1980 to 2014
In a study reported in JAMA, Ali H. Mokdad, PhD, and colleagues from the University of Washington, Seattle, found that cancer mortality rates in the United States dropped from 240.2 to 192.0 per 100,000 population between 1980 and 2014.1 Mortality rates varied widely among U.S. counties for...
Expert Point of View: George Demetri, MD
“I am intrigued by this study. I have no idea by which molecular mechanism this [tumor-treating fields therapy] works, but the data are the data,” said George Demetri, MD, of Dana-Farber Cancer Center, Boston. Dr. Demetri moderated the press conference where these data were discussed. “A panoply...
‘Out-of-the-Box’ Approach Plus Temozolomide Extends Survival in Glioblastoma
Using a novel approach called tumor-treating fields—which involves the delivery of low-intensity electric fields to the brain by a patient-operated device—along with standard-of-care temozolomide therapy improved overall survival and progression-free survival vs temozolomide alone in patients with...
Selected Clinical Trials of CDK4/6 Inhibitors
This Clinical Trials Resource Guide includes a selection of actively recruiting clinical trials of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib in multiple tumor types. All of the studies here and many others are listed on the National...
First-in-Human Experience With Abemaciclib
The investigational cyclin D–dependent kinase (CDK) 4/6 inhibitor abemaciclib was recently evaluated in several solid tumor types in a phase I multicenter trial.1 Given primarily as a single agent and with continuous dosing, abemaciclib showed encouraging early signals of clinical activity not only ...
CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future
Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors. Mechanism of Action How do CDK4/6 inhibitors work at the cellular level in...
CDK4/6 Inhibitors: Their Role in Breast Cancer
The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...
Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting
The novel mechanism of action of drugs that inhibit the cyclin D–dependent kinases CDK4 and CDK6 has prompted effective new treatment strategies. Although the bulk of the data supporting the use of selective CDK4/6 inhibitors is currently in breast cancer, patients with other tumor types are...
Continuing Education Information
This CE/CME/CEU-accredited supplement is jointly provided by To earn credit/contact hours, you must read all the articles in this supplement and then go to: https://education.annenberg.net/cdk46inhibition Release date: May 10, 2017 Expiration date: May 10, 2018Annenberg Center for Health...
ELCC 2017: Men May Need More Frequent Lung Cancer Screening Than Women
Men may need more frequent lung cancer screening than women, according to research to be presented by Koo et al at the 2017 European Lung Cancer Conference (ELCC). The U.S. Preventive Services Task Force recommends annual screening for lung cancer with low-dose computed tomography (CT) in adults...
Children Conceived After Fertility Treatments May Be at Increased Risk for Pediatric Cancers
Researchers at Ben-Gurion University of the Negev have found that babies born to mothers who underwent fertility treatments may be at increased risk of developing types of pediatric malignancies and neoplasms. The study, published by Wainstock et al in the American Journal of Obstetrics &...
Higher Costs for Complex Cancer Surgery May Be an Indicator of Lower-Quality Care
Higher costs for complex cancer surgery may be an indicator of worse—rather than better—quality of care, according to new research by experts at Rice University and The University of Texas MD Anderson Cancer Center. Their findings are published by Ho et al in Surgery, and provide...
European Commission Approves Nivolumab for Head and Neck Squamous Cell Carcinoma Progressing on or After Platinum-Based Therapy
On April 28, the European Commission approved nivolumab (Opdivo) as monotherapy for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults with disease progression on or after platinum-based therapy. Nivolumab is the first and only immuno-oncology treatment that has...
ASCO/CCO Clinical Practice Guideline Update: Adjuvant Therapy for Resected Non–Small Cell Lung Cancers
As reported in the Journal of Clinical Oncology by Mark G. Kris, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO and Cancer Care Ontario (CCO) have issued an update to the ASCO/CCO clinical practice guideline on adjuvant systemic therapy and adjuvant radiation therapy for stage...
Complete Surgical Metastasectomy for Patients With Metastatic Renal Cell Carcinoma May Extend Life Expectancy
Mayo Clinic researchers have discovered that surgery could more than double life expectancy for many patients with late-stage kidney cancer, giving them anywhere from 2 to almost 10 years more than they would have without the surgery. A paper published by Zaid et al in The Journal of Urology found...
FDA Approves Brigatinib for Metastatic ALK-Positive Non–Small Cell Lung Cancer
On April 28, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brigatinib (Alunbrig) for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) who have had disease progression on or are...
Potential Predictive Biomarker of Response to Crizotinib in Lung Cancer
Although the duration and magnitude of clinical response are unpredictable in patients with ALK-rearranged non–small cell lung cancer (NSCLC) treated with crizotinib (Xalkori), eventually all patients develop resistance to the drug. A study by Pailler et al evaluating whether circulating...
FDA Approves Midostaurin in Combination With Chemotherapy for Newly Diagnosed FLT3-Positive Acute Myeloid Leukemia
On April 28, 2017, the U.S. Food and Drug Administration (FDA) approved midostaurin (Rydapt) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation–positive, as detected by an FDA-approved test, in combination with standard cytarabine and...
Second Cancers May Be Deadlier in Pediatric, Adolescent, and Young Adult Patients
Second cancers in children as well as adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients aged 15 to 39 years overall, according to a new study by University of California (UC), Davis...
New 'Bone-in Culture Array' Tests Therapies for Breast Cancer Metastasis
A new laboratory technique developed by researchers at Baylor College of Medicine and other institutions can rapidly test the effectiveness of treatments for life-threatening breast cancer metastases in bone. Findings of this research were published by Wang et al in Nature Communications....
FDA Expands Approved Use of Regorafenib for Hepatocellular Carcinoma
The U.S. Food and Drug Administration (FDA) has expanded the approved use of regorafinib (Stivarga) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib (Nexavar). This is the first new FDA-approved treatment for liver cancer in...
ELCC 2017: Patients With Lung Cancer Treated With PD-1/PD-L1 Checkpoint Inhibitors May Experience Adverse Events After Influenza Vaccination
Patients with lung cancer treated with programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study measuring this effect. The results, to ...
Joint Position Statement on Management of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Hormone-Sensitive Breast Cancer
A new position statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated with aromatase inhibitors and outlines key management strategies to help prevent bone loss and related fractures. It was published by Hadji et...
Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment
In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center, along with an interdisciplinary team of colleagues at The University of Texas MD Anderson...
FDA Takes Action Against 14 Companies for Selling Illegal Cancer Treatments
On April 25, the U.S. Food and Drug Administration (FDA) posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat, or cure cancer. The products are marketed and sold without FDA approval, most commonly on ...
ILC 2017: Selective Internal Radiation Therapy vs Sorafenib in Hepatocellular Carcinoma
Results of the SARAH trial presented at the 2017 International Liver Congress (ILC) demonstrated that selective internal radiation therapy (SIRT) resulted in a median overall survival of 8.0 months compared to 9.9 months with sorafenib (Nexavar; P = .179) in patients with locally advanced ...
Noninvasive Imaging Test May Accurately Rule Out Kidney Cancers
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT (single-photon emission computed tomography plus computed tomography) to conventional CT or magnetic resonance imaging...
NCCN Survey Reveals Oncology Community Professionals’ Concerns About Financial Distress, Access to Care
Oncology community professionals are concerned about the ability of their patients to access cancer screening and treatment under the proposed American Health Care Act (AHCA), according to a survey conducted March 23–24, 2017, at the National Comprehensive Cancer Network® (NCCN®) 22nd ...
Low Cervical Cancer Screening Rates Found Among Women With Severe Mental Illness
Women enrolled in California's Medicaid program (Medi-Cal) who have been diagnosed with severe mental illness have been screened for cervical cancer at much lower rates than other women, according to a new study by researchers at the University of California, San Francisco (UCSF), published by...
Higher Rates of Bone Metastases and Increased Risk of Death in Follicular and Medullary Thyroid Cancer
In the largest-known study on bone metastases in thyroid cancer, researchers at the University of Michigan Comprehensive Cancer Center found that patients with follicular and medullary thyroid cancer had the highest rate of cancer-related bone lesions and fractures and an increased risk of death....
Breast Cancer Rates Increasing Among Asian Americans
In contrast to other racial/ethnic groups in the United States, Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years, according to findings published by Gomez et al in Breast Cancer Research and Treatment. To better understand potential contributors to...
Pigmented Vascular Tumor
Nevus Vasculaire Albumen Print, Paris, 1869 Published in 1869, Revue Photographique des Hôpitaux de Paris was the world’s first medical journal to contain real photographs. In the seven issues produced between 1869 and 1875, 245 images were used. Dr. A. de Montméja, a Parisian ophthalmologist and...
21-Gene Assay Score and Chemotherapy Decision-Making in Node-Positive Early Breast Cancer
The 21-gene recurrence score assay, Oncotype DX, determines a score that estimates the likelihood of distant recurrence of disease in women with early-stage estrogen receptor–positive breast cancer; this score is used to assess the benefit of adjuvant chemotherapy. Testing with this assay is...
10-Year Outcomes With Two Dose Levels of Imatinib in Unresectable or Metastatic GIST
Casali et al have reported 10-year progression-free and overall survival rates among patients with locally advanced unresectable or metastatic gastrointestinal stromal tumors (GISTs) receiving imatinib at 400 or 800 mg/d in the phase III European Organisation for Research and Treatment of Cancer,...
Update to ASCO Clinical Practice Guideline on Potentially Curable Pancreatic Cancer
An ASCO clinical practice guideline update, reported by Khorana et al in the Journal of Clinical Oncology, includes the recommendation of gemcitabine-capecitabine doublet therapy as an adjuvant therapy option in potentially curable pancreatic cancer. The updated recommendation (4.1) modifies the...
Keith T. Flaherty, MD, Named New Editor-in-Chief of Clinical Cancer Research
The American Association for Cancer Research (AACR) recently announced the appointment of Keith T. Flaherty, MD, as Editor-in-Chief of Clinical Cancer Research. Dr. Flaherty is Director of the Termeer Center for Targeted Therapies and Director of Clinical Research at the Massachusetts General...
Utilizing Physiatrists to Evaluate and Manage Cancer-Related Cognitive Impairment
Chemotherapy-associated cognitive dysfunction, often referred to as “chemobrain” or “chemofog,” is a common occurrence during active cancer treatment and may continue after treatment is completed. However, since treatment other than chemotherapy, including radiation therapy, surgery, and hormonal...
Addition of Buparlisib to Paclitaxel in Squamous Cell Carcinoma of the Head and Neck
In the phase II BERIL-1 trial reported in The Lancet Oncology, Soulières et al found that adding the pan-PI3K (phosphatidylinositol 3-kinase) inhibitor buparlisib to paclitaxel improved outcomes in patients with platinum-pretreated recurrent metastatic squamous cell carcinoma of the head and neck....
Link Between Obesity and Transformation of MGUS to Myeloma
In a population-based cohort study reported in the Journal of the National Cancer Institute, Su-Hsin Chang, PhD, of the Washington University School of Medicine, and colleagues found that overweight and obesity were associated with an increased risk of transformation of monoclonal gammopathy of...
Expect Questions About Continued Risk of Melanoma
Survivors of melanoma are more likely to limit their exposure to ultraviolet radiation than those who have not had the disease, but more than 10% continue to intentionally tan, according to a study published in Cancer Epidemiology, Biomarkers and Prevention.1 The study surveyed 724 people diagnosed ...
Some Melanoma Survivors Continue to Seek Sun Exposure, Risking Second, Potentially More Serious Melanoma
Long-term survivors of melanoma are more likely than those who have not been diagnosed with the disease to use sunscreen, protective clothing, and other means to limit exposure to the sun, according to a survey of melanoma survivors and controls about ultraviolet radiation exposure and protective...
Fear Has Become a Big Part of My Survivorship
Just 32 when I first felt a lump in the top of my left breast, I never expected it to be cancer or my life would irrevocably change in that instant. With no history of breast cancer in my family, I initially shook off any thoughts that I could have a serious disease and instead consoled myself...
Roger S. Lo, MD, PhD, Receives Inaugural AACR–Waun Ki Hong Award for Cancer Research
The American Association for Cancer Research (AACR) honored Roger S. Lo, MD, PhD, with the first AACR–Waun Ki Hong Award for Outstanding Achievement in Cancer Research during the 2017 AACR Annual Meeting in Washington, DC. The AACR established this award in recognition of AACR President...
